Overview

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Status:
Completed

Trial end date:
2019-12-09

Target enrollment:

Participant gender:

Summary

This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.

Phase:

Phase 3

Details

Lead Sponsor:

Puma Biotechnology, Inc.

Treatments:

Capecitabine
Lapatinib